REPL

19.0700.83%
EL

Emily Luisa Hill

Chief Financial Officer

Ms. Emily Luisa Hill serves as Chief Financial Officer at Replimune Group, Inc. since September 18, 2023. She joined Replimune Group, Inc. on September 18, 2023. She had been Chief Financial Officer at PTC Therapeutics, Inc. since June 3, 2019 until May 2023. Ms. Hill was Executive Director of Investor Relations at PTC Therapeutics, Inc. since November 2013 its Vice President of Investor Relations since January 2018 and served as its Senior Vice President and Head of Investor Relations since January 2019 until June 3, 2019. She served as Director of Investor Relations at Warner Chilcott from January 2011 to November 2012, where she was responsible for leading the function. She served as Senior Manager of Investor Relations of Genzyme from October 2008 to January 2011. She served as Biotechnology Equity Research Associate of Summer Street Research Partners from June 2007 to September 2008. She holds MBA from Boston College - Wallace E. Carroll Graduate School of Management in 2010. She holds MS in Pharmacology from Tufts University School of Medicine in 2006. She holds an MBA with a concentration in Finance from Fordham University - Graduate School of Business Administration in 2011 and a BA in Chinese and Biology from Hamilton College in 2002.

Positions